In recent years, severe adverse reactions have been reported in patients with mutations in the NUDT15 gene and wild TPMP gene after treatment with AZA, with leukopenia and alopecia being the most common,[23,29–35] indicating the necessity of determining NUDT15 activity status prior to treatment with AZA. This evidence concerns the gene NUDT15 and Decreased total leukocyte count.